Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review

References

• IDF Diabetes Atlas. 6^th edition revision; 2014
   Google Scholar
• IDF Diabetes Atlas. 6^th edition; 2013
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• FDA-approved drugs: Tricor. [ cited 2015 Jan 28]. Available from: http://www.fdaapproveddrugs.us/product.php?i=tricor-micronized&d=019304
   Google Scholar
• Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs. 2002;62:1909–1944.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34. doi:10.1016/j.jclinepi.2009.06.006.
   PubMed Web of Science ®Google Scholar
• The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370:1687–1697.
   PubMed Web of Science ®Google Scholar
• The ACCORD study group and ACCORD-Eye study group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244.
   PubMed Web of Science ®Google Scholar
• Chew EY, Davis MD, Danis RP, et al. for the Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study. Ophthalmology. 2014;121:2443–2451.
   PubMed Web of Science ®Google Scholar
• Massin P, Peto T, Ansquer J-C, et al. for the MacuFEN study investigators. Effects of fenofibric acid on diabetic macular edema: the MacuFEN study. Ophthalmic Epidemiol. 2014;21:307–317.
   PubMed Web of Science ®Google Scholar
• Ansquer J-C, Foucher C, Rattier S, et al. for the DAIS investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the diabetes atherosclerosis intervention study (DAIS). Am J Kidney Dis. 2005;45:485–493.
   PubMed Web of Science ®Google Scholar
• Davis TME, Ting R, Best JD, et al. on behalf of the FIELD study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia. 2011;54:280–290.
   PubMed Web of Science ®Google Scholar
• Forsblom C, Sundvall J, Hiukka A, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes. The FIELD Helsinki substudy. Diabetes Care. 2010;33:215–220.
   PubMed Web of Science ®Google Scholar
• Ting RD, Lehto S, Keech AC, et al. on behalf of the FIELD study investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment. The FIELD study. Diabetes Care. 2012;35:218–225.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. for the ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Mychaleckyj JC, Lorber D, Craven T, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35:1008–1014.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55:1641–1650.
   PubMed Web of Science ®Google Scholar
• Rajamani K, Colman PG, Li LP, et al. on behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373:1780–1788.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136.
   PubMed Web of Science ®Google Scholar
• Australian Public Assessment Report for fenofibrate: therapeutic Goods Administration. [ cited 2015 Jan 28]. Available from: https://www.tga.gov.au/file/6794/download
   Google Scholar
• Hu Y, Chen Y, Ding L, et al. Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proct Natl Acad Sci. 2013;110:15401–15406.
   PubMed Web of Science ®Google Scholar
• Sasongko MB, Wong TY, Nguyen TT, et al. Novel versus traditional risk markers for diabetic retinopathy. Diabetologia. 2012;55:666–670.
   PubMed Web of Science ®Google Scholar
• Simo R, Garcia-Ramirez M, Higuera M, et al. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Opthalmol. 2009;147:319–325.
   PubMed Web of Science ®Google Scholar
• Bogdanov P, Hernández C, Corraliza L, et al. Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetol. 2015;52:113–122.
   PubMed Web of Science ®Google Scholar
• Abcouwer SF. Direct effects of PPAR-α agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes. 2013;62:36–38.
   PubMed Web of Science ®Google Scholar
• Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:32–43.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
   PubMed Web of Science ®Google Scholar
• Malik RA, Tesfaye S, Ziegler D. Medical strategies to reduce amputation in patients with type 2 diabetes. Diabet Med. 2013;30:893–900.
   PubMed Web of Science ®Google Scholar